• linkedin
  • Increase Font
  • Sharebar

    Experimental prostate Ca urinary test outperforms PSA

    The experimental ExoDx Prostate IntelliScore urine exosome assay (Exosome Diagnostics) outperformed the PSA test for detecting high-grade prostate cancer on biopsy, according to a new study.

    Also see: How RT dose escalation affects prostate Ca outcomes

    One prostate cancer expert told Urology Times that while the assay shows promise, head-to-head studies are needed to compare tests such as IntelliScore with currently available tests to determine who best benefits from each test.

    The urinary three-gene expression assay noninvasively discriminates among high-grade Gleason score ≥7, and low-grade Gleason 6 cancer, and benign disease by detecting RNA from three genes, ERG, PCA3, and SPDEF, which are associated with prostate cancer development and progression.

    For the study, which was published online in JAMA Oncology (March 31, 2016), researchers compared prostate biopsy results from 774 men with PSA levels between 2.0 ng/mL and 10.0 ng/mL with a composite score based on results of the urine test, along with PSA level, age, race, and family history of prostate cancer. They then set a cut-off score of 15.6, based on the use of data from 255 of the men, which showed that score identified more than 90% of men with high-grade cancer. To study the test’s accuracy, the authors used the 15.6 score on the remaining 519 men to predict who had high-grade cancer versus low-grade cancer or no disease.

    Read: Utility of PCa markers in African-Americans differs

    They reported the urine exosome assay identified 92% of men with high-grade cancer. The test also predicted high-grade cancer in 66% of men whose biopsies revealed low-grade or no cancer. Using the cut-off score, 27% of biopsies (138 of 519) would have been avoided.

    Next: Test "could reduce hundreds of thousands of invasive biopsies each year"

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available